Onasemnogene abeparvovec commonly linked to hepatotoxicity
Hepatotoxicity is common after treatment with onasemnogene abeparvovec for spinal muscular atrophy, a recent study has found. Clinicians should anticipate and be ready to manage such adverse events, and be aware of any potential underlying conditions that could aggravate them.
